Erasca, Inc.

NASDAQ:ERAS

Biotechnology

Healthcare
$13.76 -0.14%

-$0.02 today

Market cap
$4.83B
Beta
0.73
P/E (TTM)
-15.3
EPS (TTM)
-$0.91
52W Low $1.21High $24.28

Volume 8.94M

Average 6.79M

ERAS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Erasca, Inc.NASDAQ: ERAS

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA remains negative

Q3 FY2026 EBITDA was -$50.62M, compared with -$29.86M a year earlier. Trailing-twelve-month EBITDA was -$305.05M.

Context

  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 5 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +20.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$50.62M-16.7% QoQ
Last fiscal yearDec 2025
-$121.44M+20.8% YoY
LTMSep 2026
-$305.05M-151.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-69.5%+100.0%+169.5 pp
1 year+20.8%+100.0%+79.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(121.44M) USD
Year-over-year change
+20.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ERAS compares with its peers on the latest reported figures

  • ERAS's LTM Sep 2026 EBITDA of -$305.05M is the 8th highest of the 9 companies compared; the peer median is -$168.6M.
  • Its year-over-year change of -151.6% is the lowest of 9, against a peer median of -23.1%.
ERAS Competitors Peer median
EBITDA for ERAS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NUVBNuvation Bio Inc.LTM Jun 2026-$127.04M +36.8%—74.8%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026-$134.03M -1.8%——
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-$135.46M +55.2%—60.1%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026-$145.24M -14.0%——
VSTMVerastem, Inc.LTM Mar 2026-$191.95M -32.3%—387.1%
TNGXTango Therapeutics, Inc.LTM Sep 2026-$206.26M -110.5%——
KURAKura Oncology, Inc.LTM Mar 2026-$292.27M -64.2%—408.0%
ERASErasca, Inc.LTM Sep 2026-$305.05M -151.6%——
RVMDRevolution Medicines, Inc.LTM Jun 2026-$1.69B -111.6%——
Peer median (excluding ERAS) -$168.6M-23.1%—230.9%

Competitors are the stored peer set for ERAS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue829K2.64M3.73M03.11M
Gross Profit(829K)(2.64M)(3.73M)0(3.11M)
Gross Margin—————
Research & Development73.92M112.46M103.82M115.36M92.85M
Selling, General & Admin22.62M32.99M37.7M41.73M38.55M
Operating Expenses124.05M244.81M137.79M179.59M128.3M
Depreciation & Amortization829K2.64M3.73M3.81M3.11M
EBITDA(121.94M)(240.16M)(121.31M)(153.28M)(121.44M)
EBITDA Margin—————
Operating Income(124.88M)(247.45M)(141.53M)(179.59M)(131.41M)
Operating Margin—————
Interest Income190K4.9M16.71M20.09M16.61M
Interest Expense0201.36M000
Other Income / Expenses2.12M4.65M16.48M17.94M6.86M
Income Before Tax(122.76M)(242.81M)(125.04M)(161.65M)(124.55M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(122.76M)(242.81M)(125.04M)(161.65M)(124.55M)
Net Margin—————
EPS (Basic)(1.03)(1.99)(0.83)(0.69)(0.44)
EPS (Diluted)(1.03)(1.99)(0.83)(0.69)(0.44)
Weighted Avg Shares119.1M122.02M150.18M233.82M283.53M
Weighted Avg Shares (Diluted)119.1M122.02M150.18M233.82M283.53M

Erasca, Inc.

NASDAQ:ERAS

Intrinsic Alpha fair value

Locked

Current Price

$13.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.